Loading...
XSHG
600276
Market cap55bUSD
Dec 05, Last price  
61.62CNY
1D
0.60%
1Q
-14.97%
Jan 2017
111.27%
IPO
174.72%
Name

Jiangsu Hengrui Pharmaceuticals Co Ltd

Chart & Performance

D1W1MN
XSHG:600276 chart
P/E
62.03
P/S
14.05
EPS
0.99
Div Yield, %
0.33%
Shrs. gr., 5y
—
Rev. gr., 5y
3.74%
Revenues
27.98b
+22.63%
1,179,259,5571,422,456,9041,959,660,1212,392,561,1593,028,960,8813,744,106,2694,550,391,7685,435,067,5616,203,074,3557,452,253,0879,315,960,16811,093,724,12113,835,629,36917,417,901,05023,288,576,60727,734,598,74725,905,526,37521,275,270,68122,819,784,74127,984,605,342
Net income
6.34b
+47.28%
162,222,057206,647,797412,921,287422,947,064665,730,889724,173,302876,611,0611,077,384,7641,238,110,6351,515,568,8632,171,571,5452,588,952,0953,216,647,9984,065,609,7165,328,027,5196,328,383,2194,530,217,5503,906,375,0674,302,435,9306,336,527,014
CFO
7.42b
-2.89%
227,876,230266,175,427218,873,724117,459,736439,116,229385,945,810527,357,720958,368,8911,364,958,6661,574,306,0242,277,293,1222,592,628,3952,547,385,4162,774,212,7343,816,832,8673,431,934,8054,218,816,0531,265,264,6317,643,665,0747,422,753,038
Dividend
Jul 12, 20240.2 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.
URL
https://www.hengrui.com/
IPO date
Oct 18, 2000
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT